Inventor
OSTROFF GARY R
US36 patents
⚠️ This page may combine multiple inventors who share the name “OSTROFF GARY R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALPHA BETA TECHNOLOGY
15 patentsUS5741495AApr 21, 1998
Glucan drug delivery system and adjuvant
ALPHA BETA TECHNOLOGY152 citations99
US5622939AApr 22, 1997
Glucan preparation
ALPHA BETA TECHNOLOGY104 citations99
US5607677AMar 4, 1997
Glucan drug delivery system and adjuvant
ALPHA BETA TECHNOLOGY321 citations99
US5504079AApr 2, 1996
Method for immune system activation by administration of a β(1-3) glucan which is produced by Saccharomyces cerevisiae strain R4
ALPHA BETA TECHNOLOGY180 citations99
US5032401AJul 16, 1991
Glucan drug delivery system and adjuvant
ALPHA BETA TECHNOLOGY297 citations99
US5322841AJun 21, 1994
Method for producing neutral glucans for pharmaceutical applications
ALPHA BETA TECHNOLOGY109 citations97
US5849720ADec 15, 1998
Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans
ALPHA BETA TECHNOLOGY78 citations96
US5817643AOct 6, 1998
Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same
ALPHA BETA TECHNOLOGY93 citations96
US5811542ASep 22, 1998
Method for producing soluble glucans
ALPHA BETA TECHNOLOGY82 citations96
US5783569AJul 21, 1998
Uses for underivatized, aqueous soluble β(1-3) glucan and compositions comprising same
ALPHA BETA TECHNOLOGY78 citations96
US5663324ASep 2, 1997
Method for producing underivatized, aqueous soluble β(1-3) glucan
ALPHA BETA TECHNOLOGY58 citations96
US5633369AMay 27, 1997
Method for producing soluble glucans
ALPHA BETA TECHNOLOGY57 citations96
US5622940AApr 22, 1997
Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
ALPHA BETA TECHNOLOGY84 citations96
US5532223AJul 2, 1996
Use of aqueous soluble glucan preparations to stimulate platelet production
ALPHA BETA TECHNOLOGY80 citations96
US5488040AJan 30, 1996
Use of neutral soluble glucan preparations to stimulate platelet production
ALPHA BETA TECHNOLOGY79 citations96
UNIV MASSACHUSETTS
9 patentsUS7740861B2Jun 22, 2010
Drug delivery product and methods
UNIV MASSACHUSETTS37 citations96
US11844815B2Dec 19, 2023
Purified anthelmintic compositions and related methods
UNIV MASSACHUSETTS2 citations70
US11826389B2Nov 28, 2023
Purified anthelmintic compositions and related methods
UNIV MASSACHUSETTS2 citations70
US9662299B2May 30, 2017
Yeast cell wall particles for receptor-targeted nanoparticle delivery
UNIV MASSACHUSETTS3 citations68
US11484568B2Nov 1, 2022
Anthelmintic compositions and methods
UNIV MASSACHUSETTS4 citations65
US8007814B2Aug 30, 2011
Therapy for lysosomal enzyme deficiencies
UNIV MASSACHUSETTS3 citations61
US12576129B2Mar 17, 2026
Anthelmintic compositions and methods
UNIV MASSACHUSETTS0 citations60
US12290539B2May 6, 2025
Purified anthelmintic compositions and related methods
UNIV MASSACHUSETTS0 citations60
US9682135B2Jun 20, 2017
Drug delivery product and methods
UNIV MASSACHUSETTS0 citations52
OSTROFF GARY R
4 patentsUS8580275B2Nov 12, 2013
Drug delivery product and methods
OSTROFF GARY R10 citations83
US9242857B2Jan 26, 2016
Yeast cell wall particles for receptor-targeted nanoparticle delivery
OSTROFF GARY R2 citations57
US8865679B2Oct 21, 2014
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
OSTROFF GARY R1 citations51
US8563531B2Oct 22, 2013
Methods of using beta glucan as a radioprotective agent
OSTROFF GARY R1 citations47
BIOPOLYMER ENGINEERING INC
3 patentsUS7022685B2Apr 4, 2006
Very high molecular weight β-glucans
BIOPOLYMER ENGINEERING INC43 citations94
US7786094B2Aug 31, 2010
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
BIOPOLYMER ENGINEERING INC5 citations73
US7566704B2Jul 28, 2009
Very high molecular weight β-glucans
BIOPOLYMER ENGINEERING INC5 citations72